Acid Inhibitory Characteristics of Nizatidine in Man: An Overview

References

• Callaghan J T, Bergstrom R F, Rubin A, et al. A pharmacokinetic profile of nizatidine in man. Scand J Gastroenterol 1987; 22(Suppl 136)9–17
   Google Scholar
• Knadler M P, Rubin A, Bergstrom R F, et al. Nizatidine, an H2-blocker: its metabolism and disposition in man. Drug Metabol Dispos 1986; 14: 175–82
   PubMed Web of Science ®Google Scholar
• Klotz U. Lack of effect of nizatidine on drug metabolism. Scand J Gastroenterol 1987; 122: 41–6, Suppl
   Google Scholar
• Van Thiel D H, Gavaler J S, Heyl A, Susen B. An evaluation of the anti-androgen effects associated with H2-antagonist therapy. Scand J Gastroenterol 1987; 122: 24–8, Suppl
   Google Scholar
• Price A H, Brogden R N. Nizatidine: a preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in peptic ulcer disease. Drugs 1988; 521–39
   PubMedGoogle Scholar
• Ryan J R, Vargas R, McMahon F G, et al. Dose-response efficacy of intravenous nizatidine on gastric secretion and acidity. Am J Gastroenterol 1986; 81: 857
   Google Scholar
• You C H, Lee S I, Chey W Y. The effect of a new H2-blocker (nizatidine) on gastric acid secretion: comparison with cimetidine. Gastroenterology 1985; 88: 1639
   Google Scholar
• Linscheer W G, Raheja K L, Hirose N. A double-blind controlled study proves nizatidine to be much more potent than cimetidine. Gastroenterology 1985; 88: 1478
   Google Scholar
• Hammond J B, Offen W W. Effect of nizatidine and cimetidine on betazole-stimulated gastric acid secretion of normal subjects: comparison of effects on acid, water and pepsin. Am J Gastroenterol 1988; 83: 32–6
   PubMedGoogle Scholar
• Missale G, Agosti A, Bertele A. Inhibition of gastric acid section in man by nizatidine and ranitidine. Ital J Gastroenterol 1987; 19: 261–3
   Google Scholar
• Lazzaroni M, Porro Bianchi G. The effect of an oral morning dose of nizatidine and ranitidine on gastric acid secretion in duodenal ulcer patients. Hepatogastroenterol 1989; 36: 490–3
   PubMedGoogle Scholar
• Cunningham M, Malè P-J, Striberni R, Loizeau E. Twenty-four hour H+ activity, nocturnal acid and pepsin output on a new H2-receptor antagonist nizatidine. Am J Gastroenterol 1985; 80: 839
   Google Scholar
• Di Mario F, Vianello F, Tessaro P, et al. Ranitidine and nizatidine action on peptic secretion. Gastroenterology 1987; 92: 1371
   Google Scholar
• Damman J G, Gottlieb W R, Walter T A, et al. The 24-hour acid suppression profile of nizatidine. Scand J Gastroenterol 1987; 22(Suppl 136)56–60
   Google Scholar
• Lanzon-Miller S, Pounder R E, Chronos N A, et al. Twenty-four hour intragastric acidity and plasma gastrin concentration in healthy volunteers taking nizatidine 150 mg, nizatidine 300 mg, ranitidine 300 mg, or placebo at 2100h. Gut 1988; 29: 1364–9
   PubMed Web of Science ®Google Scholar
• Savarino V, Mela G S, Zentilin P, et al. Comparison of the effects of placebo, ranitidine, famotidine and nizatidine on intragastric acidity by means of continuous pH recording. Digestion 1989; 42: 1–6
   PubMed Web of Science ®Google Scholar
• Savarino V, Mela G S, Zentilin P, et al. Twenty-four hour control of gastric acidity by twice-daily doses of placebo, nizatidine 150 mg, nitazidine 300 mg, and ranitidine 300 mg. J Clin Pharmacol 1993; 33: 70–4
   PubMedGoogle Scholar
• Bauerfeind P, Cilluffo T, Emde C, et al. Reduction of gastric acidity with ranitidine or famotidine: early evening dose is more effective than late evening dosage. Digestion 1987; 37: 217–22
   PubMed Web of Science ®Google Scholar
• Merki H, Witzel L, Harre K, et al. Single dose treatment with H2-receptor antagonists: is bedtime administration too late?. Gut 1987; 28: 451–4
   PubMed Web of Science ®Google Scholar
• Merki H, Witzel L, Huttemann W, et al. Early evening ranitidine administration promotes faster duodenal ulcer healing. Am J Gastroenterol 1988; 83: 362–4
   PubMed Web of Science ®Google Scholar
• Duroux P, Emde C, Bauerfeind P, et al. Early evening nizatidine intake with a meal optimizes the antisecretory effect. Aliment Pharmacol Ther 1993; 7: 47–54
   PubMedGoogle Scholar
• Porro Bianchi G, Parente F, Sangaletti O. Inhibition of nocturnal acidity is important but not essential for duodenal ulcer healing. Gut 1990; 31: 397–400
   PubMedGoogle Scholar
• De Pretis G, Dobrilla G, Ferrari A, et al. Comparison between single morning and bedtime doses of 40 mg famotidine for the treatment of duodenal ulcer. Aliment Pharmacol Therap 1989; 3: 285–91
   PubMedGoogle Scholar
• Savarino V, Mela G S, Zentilin P, et al. Single morning and nightly doses of ranitidine 300 mg: an appraisal of their antisecretory effects by continuous pH monitoring. Digestion 1991; 48: 141–8
   PubMedGoogle Scholar
• Lazzaroni M, Sangaletti O, Porro Bianchi G. The effect of a single oral dose of nizatidine and ranitidine on intragastric pH under basal conditions and after pentagastrin stimulation. J Int Med Res 1992; 20: 454–60
   PubMedGoogle Scholar
• Fullarton G M, McLauchlan G, Macdonald A, et al. Rebound nocturnal hypersecretion after four weeks treatment with an H2-receptor antagonist. Gut 1989; 30: 449–54
   PubMed Web of Science ®Google Scholar
• Fullarton G M, Macdonald A, McColl K EL. Rebound hypersecretion after H2-antagonist withdrawal - a comparative study with nizatidine, ranitidine and famotidine. Aliment Pharmacol Therap 1991; 5: 391–8
   PubMedGoogle Scholar
• Nwokolo C U, Smith J T, Sawyerr A M, Pounder R E. Rebound intragastric hyperacidity after abrupt withdrawal of histamine H2-receptor blockade. Gut 1991; 32: 1455–60
   PubMed Web of Science ®Google Scholar
• Savarino V, Mela G S, Zentilin P, et al. Lack of gastric acid rebound after stopping a successful short-term course of nizatidine in duodenal ulcer patients. Am J Gastroenterol 1991; 86: 281–4
   PubMedGoogle Scholar
• Smith J T, Gavey C, Nwokolo C U, et al. Tolerance during 8 days of high-dose H2-blockade: placebo-controlled studies of 24-h acidity and gastrin. Aliment Pharmacol Therap 1990; 4: 47–63
   PubMed Web of Science ®Google Scholar
• Wilder-Smith C H, Ernst T, Gennoni M, et al. Tolerance to oral H2-receptor antagonists. Dig Dis Sci 1990; 35: 976–83
   PubMed Web of Science ®Google Scholar
• Nwokolo C U, Smith J T, Gavey C, et al. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment Pharmacol Therap 1990; 4: 29–45
   PubMed Web of Science ®Google Scholar
• Bonfils S. Nizatidine versus ranitidine: evolution of drug antisecretory efficacy over a 28-day period. Curr Ther Res Clin Exp 1992; 52: 859–62
   Google Scholar